Open Now: The Global ETF Survey Take the Survey →

Advertisement
Advertisement

XLVIvsFTXHETF Comparison

ETF 1
XLVI

State Street Health Care Select Sector SPDR Premium Income Fund

This fund is part of
Options Strategies
-0.17%
VS
ETF 2
FTXH

First Trust Nasdaq Pharmaceuticals ETF

This fund is part of
US Health Care
+0.15%

State Street Health Care Select Sector SPDR Premium Income Fund (XLVI) belongs to the Options Strategies segment. First Trust Nasdaq Pharmaceuticals ETF (FTXH) is part of the US Health Care segment. XLVI's top 3 sector exposures are Healthcare and Consumer Non-Cyclicals. In contrast, FTXH's top sector exposures are Healthcare  XLVI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.6% for FTXH. XLVI is up 5.2% year-to-date (YTD) with +$7M in YTD flows. FTXH performs better with 18.29% YTD performance, and +$68M in YTD flows. Run a side-by-side ETF comparison of XLVI and FTXH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

XLVI vs FTXH performance and flow charts

Performance

0246810%Jun 22Jun 29Jul 6Jul 13Jul 20

Cumulative Flows

0 M10 M20 M30 M40 M50 M60 MJun 22Jun 29Jul 6Jul 13Jul 20

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows
Data as of 07/22/2026
1M3MYTD1Y3Y5Y
Perf.
XLVI
FTXH
+3.88%+7.11%
+7.81%+14.47%
+5.20%+18.29%
n/a+45.19%
n/a+51.79%
n/a+57.01%
Flows
XLVI
FTXH
+$2M+$58M
+$5M+$61M
+$7M+$68M
-+$71M
-+$60M
-+$63M
Volatility and drawdown
3M1Y3Y5Y
Volatility
XLVI
FTXH
+12.38%+18.19%
n/a+17.07%
n/a+16.58%
n/a+16.09%
Max drawdown
XLVI
FTXH
-2.06%-4.43%
n/a-7.50%
n/a-19.32%
n/a-19.32%
Max drawdown duration
XLVI
FTXH
7d16d
n/a99d
n/a393d
n/a393d
Trading data

Create an account to view trading data

Join for free
XLVI
FTXH
Last sale
7/24/2026 at 1:30 PM
$26.52
$38.97
Previous close
07/23/2026
$26.33
$38.83
Consolidated volume
07/23/2026
Average volume
30 days
Average discount or premium
30 days
Average Bid/Ask spread
30 days
Replication quality
Data as of June 30, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free

XLVI
is actively managed and doesn’t replicate an index

Create an account to view replication quality

Join for free
XLVI
FTXH
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
XLVI
FTXH
Last price
$26.52
$38.97
1D performance
+0.72%
+0.37%
AuM$18.27 M$95.03 M
E/R0.35%0.6%
Characteristics
XLVI
FTXH
Management strategyActivePassive
ProviderState Street Investment ManagementFirst Trust
Benchmark-NASDAQ US Smart Pharmaceuticals Index
N° of holdings5950
Asset class-Equities
Trailing 12m distribution yield
Join
Join
Inception dateJuly 30, 2025September 20, 2016
ESGNoNo
Advertisement
Exposure

Countries

XLVI
USA
100.53%
Other
-0.53%
FTXH
USA
95.49%
Other
4.51%

Sectors

XLVI
Healthcare
100.33%
Other
-0.33%
FTXH
Healthcare
99.86%
Other
0.14%

Diversification

XLVI

Total weight of top 15 holdings out of 15

74.76%
FTXH

Total weight of top 15 holdings out of 15

66.57%

Top 15 holdings

Data as of June 30, 2026
XLVI
Eli Lilly & Co.
17.01%
Johnson & Johnson
10.96%
AbbVie, Inc.
7.97%
UnitedHealth Group, Inc.
6.77%
Merck & Co., Inc.
5.69%
Amgen, Inc.
3.50%
Thermo Fisher Scientific, Inc.
3.34%
Abbott Laboratories
2.83%
Gilead Sciences, Inc.
2.81%
Intuitive Surgical, Inc.
2.53%
Pfizer Inc.
2.46%
CVS Health Corp.
2.37%
Vertex Pharmaceuticals, Inc.
2.26%
Danaher Corp.
2.15%
Bristol Myers Squibb Co.
2.11%
FTXH
Eli Lilly & Co.
7.74%
AbbVie, Inc.
7.39%
Johnson & Johnson
6.98%
Merck & Co., Inc.
6.92%
Bristol Myers Squibb Co.
6.18%
Biogen, Inc.
3.73%
Viatris, Inc.
3.70%
Cardinal Health, Inc.
3.54%
Vertex Pharmaceuticals, Inc.
3.42%
Amgen, Inc.
3.18%
Pfizer Inc.
2.95%
Gilead Sciences, Inc.
2.89%
United Therapeutics Corp.
2.76%
Regeneron Pharmaceuticals, Inc.
2.73%
Jazz Pharmaceuticals Plc
2.46%
Frequently asked questions about XLVI and FTXH

How have the XLVI and FTXH ETFs performed in 2026?

As of July 22, 2026, XLVI is up 5.2% year-to-date (YTD), while FTXH has returned 18.29%. That puts FTXH better performer ahead so far this year.

Which ETF is attracting more investor money: XLVI or FTXH?

Year-to-date, the XLVI ETF saw +$7M in flows, compared to +$68M for FTXH.

Which ETF is bigger: XLVI or FTXH?

As of July 22, 2026, XLVI holds $18.27 M in assets under management (AUM), while FTXH manages $95.03 M.

What sectors do the XLVI and FTXH ETFs invest in?

XLVI leans toward sectors like Healthcare. Meanwhile, FTXH focuses on Healthcare.

What are the top holdings of the XLVI ETF and FTXH ETF?

XLVI top holdings include Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc.. FTXH holds in its top three: Eli Lilly & Co., AbbVie, Inc. and Johnson & Johnson.

Which ETF is more diversified: XLVI or FTXH?

XLVI holds 59 securities with 74.76% of its assets in the top 15. FTXH has 50 securities and a top 15 weight of 66.57%.

Advertisement
Advertisement
Advertisement
ETF INVESTOR RESOURCES

Expert-Built ETF Portfolios, All in One Place

Don’t start from scratch. Discover ready-made ETF portfolios built by professionals to match different goals, timelines, and market views. Use them as inspiration or as a starting point for your own allocation.

Portfolio Builder